Table 54 Table displays the mobilization outcomes for each diagnosis by mobilisation regimen.

Multiple Myeloma

Number of patients

438

319

45

Pre-CD34+ count

(x10⁶/kg)

Median (Q1-Q3)

29 (18–54)

40 (21–75)

23 (15–53)

<0.0001

ns

<0.0001

CD34+ yield per procedure

(x10⁶/kg)

Median (Q1-Q3)

2.01 (1.16–3.30)

3.65 (1.87–6.23)

2.01 (1.20–5.04)

<0.0001

ns

<0.0001

CD34+ yield per patient

(x10⁶/kg)

Median (Q1-Q3)

4.75 (3.47–6.3)

7.44 (5.44–9.61)

5.75 (3.72–7.84)

<0.0001

ns

<0.0001

Plerixafor use

N (%)

41 (9.3%)

11 (3.4%)

15 (33%)

<0.001

<0.00001

<0.00001

NHL

Number of patients

142

47

189

Pre-CD34+ count

(x10⁶/kg)

Median (Q1-Q3)

23 (14–43)

19 (11–30)

28 (15–72)

NS

NS

0.0055

CD34+ yield per procedure

(x10⁶/kg)

Median (Q1-Q3)

1.53 (0.89–3.19)

1.19 (0.80-3.04)

2.93 (1.30-5.87)

NS

<0.00001

<0.00001

CD34+ yield per patient

(x10⁶/kg)

Median (Q1-Q3)

3.70 (2.65–5.89)

3.69 (2.60–6.50)

5.98 (3.85–8.93)

NS

<0.00001

<0.00001

Plerixafor use

N (%)

37 (26%)

4 (9%)

37 (20%)

0.011

NS

NS

Hodgkin’s Lymphoma

Number of patients

44

16

30

Pre-CD34+ count

(x10⁶/kg)

Median (Q1-Q3)

33 (16–63)

35 (18–64)

37 (16–63)

NS

NS

NS

CD34+ yield per procedure

(x10⁶/kg)

Median (Q1-Q3)

1.94 (0.97–4.78)

3.02 (1.61–6.85)

2.10 0/96–4.38)

NS

NS

NS

CD34 yield per patient

Median (Q1-Q3)

4.53 (2.99–7.44)

5.52 (3.02–5.52)

4.32 (2.99–8.05)

NS

NS

NS

Plerixafor use

N (%)

6 (14%)

2 (9 %)

8 (27%)

NS

NS

NS